Avelumab and Merkel Cell Carcinoma: Examining Biological Plausibility

From General Health to Occupational Exposure

The legacy of general health and science communication has long emphasized the importance of understanding how environmental and pharmaceutical exposures may influence disease risk. Within this broad framework, public health messaging has historically focused on lifestyle factors and infectious agents, while occupational health considerations have often been treated as a specialized subset. As scientific inquiry advances, the boundary between general population health and workplace-related exposures becomes increasingly porous. This is particularly relevant when examining therapeutic agents that, while designed to treat disease, may themselves carry unintended risks under specific exposure conditions. The transition from general health education to occupational exposure concern requires careful attention to the biological plausibility of such associations without overstating mechanistic certainty. In the context of mass production environments, workers may encounter pharmaceutical compounds at concentrations or durations not typical for patients receiving monitored therapy. This shift in perspective—from patient-centered risk assessment to occupational exposure evaluation—demands a rigorous examination of how a given agent might plausibly contribute to adverse outcomes under industrial exposure scenarios. The following discussion addresses this transition by considering the biological plausibility of an association between avelumab exposure and Merkel cell carcinoma risk, moving from general health awareness toward a focused occupational health perspective.

Biological Mechanisms of Avelumab

Avelumab is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096). It is approved in the USA, the EU, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive neuroendocrine cutaneous malignancy with poor prognosis (https://pubmed.ncbi.nlm.nih.gov/29799096; https://pubmed.ncbi.nlm.nih.gov/33439294). The approval was based on the JAVELIN Merkel 200 phase II trial, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC treated with avelumab (https://pubmed.ncbi.nlm.nih.gov/29799096). However, the biological plausibility of avelumab causing or contributing to Merkel cell carcinoma requires careful examination of mechanistic pathways, clinical presentation, and risk considerations.

Merkel Cell Carcinoma Etiology and Avelumab's Role

Merkel cell carcinoma has two primary etiologies: approximately 80% of cases are caused by the human Merkel cell polyomavirus (MCPyV), while the remaining 20% are induced by UV light leading to mutations (https://pubmed.ncbi.nlm.nih.gov/34445385). The standard treatment for metastatic MCC includes anti-PD-1/PD-L1 immune checkpoint inhibitors such as avelumab, which show better overall response rates and longer duration of responses compared to conventional chemotherapy (https://pubmed.ncbi.nlm.nih.gov/34445385). Nevertheless, about 50% of patients do not respond or develop immune-related adverse events (irAEs) due to mechanisms such as down-regulation of MHC complexes or induction of anti-inflammatory cytokines (https://pubmed.ncbi.nlm.nih.gov/34445385). Avelumab is known to cause overactivation of the immune system, leading to irAEs, including a reported case of hypercalcemia secondary to reactivation of sarcoidosis in a patient with metastatic MCC on avelumab (https://pubmed.ncbi.nlm.nih.gov/31543781). This indicates that avelumab can trigger immune-mediated inflammatory responses, but there is no direct evidence from the provided sources that avelumab causes de novo Merkel cell carcinoma.

Evidence for Avelumab as Treatment, Not Cause

The mechanistic pathways linking avelumab to MCC are primarily therapeutic rather than causative. Avelumab blocks PD-L1, enhancing T-cell responses against tumor cells, including those in MCC (https://pubmed.ncbi.nlm.nih.gov/34445385). In avelumab-refractory patients, subsequent treatment with ipilimumab plus nivolumab has shown responses in three out of five patients in a retrospective study (https://pubmed.ncbi.nlm.nih.gov/33439294). Another multicenter study reported that immune checkpoint inhibition has significantly improved treatment outcomes in metastatic MCC, with response rates to PD-1/PD-L1 inhibition of up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381). These data support avelumab's role as a treatment for MCC, not as a cause. The biological plausibility of avelumab causing MCC would require evidence that the drug induces oncogenic transformation or promotes tumor growth, which is not supported by the provided evidence. Instead, avelumab is used to treat existing MCC, and its adverse effects are primarily immune-related, such as irAEs, rather than carcinogenic.

Risk Context and Causation Considerations

Risk anchors include the adequacy of warnings regarding avelumab and MCC. The provided evidence does not include specific warning labels or regulatory communications, but the known adverse effects of avelumab are documented in clinical trials and case reports, such as immune-related hypercalcemia (https://pubmed.ncbi.nlm.nih.gov/31543781). For affected patients, causation-related considerations must distinguish between avelumab as a treatment for MCC and a potential causal role. The timeline between exposure and documented harm is relevant: in the JAVELIN Merkel 200 trial, avelumab was administered to patients with pre-existing MCC, and responses were measured over weeks to months (https://pubmed.ncbi.nlm.nih.gov/29799096). There is no evidence of avelumab causing new-onset MCC after exposure. In the case of hypercalcemia due to sarcoidosis reactivation, the adverse event occurred during treatment and resolved with corticosteroids, allowing continued avelumab therapy (https://pubmed.ncbi.nlm.nih.gov/31543781). This suggests that irAEs can develop during treatment, but they are not indicative of carcinogenesis. In summary, the evidence supports avelumab as an effective treatment for metastatic MCC, with a mechanism of action that enhances immune response against tumor cells. There is no biological plausibility from the provided sources that avelumab causes Merkel cell carcinoma. The drug's adverse effects are immune-mediated, and warnings should address irAEs rather than carcinogenic risk. For patients, the primary causation consideration is that avelumab is used to treat MCC, not to induce it. The timeline of exposure and harm is consistent with therapeutic use and immune-related events, not with de novo cancer development.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

Can avelumab cause Merkel cell carcinoma?

Based on current evidence, avelumab is not known to cause Merkel cell carcinoma. It is used as a treatment for metastatic MCC, and its mechanism of action enhances the immune response against tumor cells. There is no evidence that avelumab induces oncogenic transformation or promotes tumor growth.

What are the main adverse effects of avelumab?

Avelumab can cause immune-related adverse events (irAEs) due to overactivation of the immune system, such as hypercalcemia secondary to sarcoidosis reactivation. These effects are immune-mediated and not indicative of carcinogenic risk.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Avelumab exposure and a confirmed Merkel Cell Carcinoma diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.